Drugs / VESENCUMAB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00954642 | Aug 2009 → Dec 2011 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00747734 | Sep 2008 → ? | solid adenocarcinoma with mucin production | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VESENCUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743089 ↗ |
| Known as | MNRP1685A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00747734 ↗ |
| Known as | RG-7347 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743089 ↗ |
| Action | Inhibit | “Neuropilin-1 inhibitor” CHEMBL1743089 ↗ |
| Modality | Monoclonal antibody | “a Human IgG1 Antibody” NCT00747734 ↗ |
| Route | Intravenous | “administered intravenously” NCT00747734 ↗ |
| Target | NRP1 | “Neuropilin-1 inhibitor” CHEMBL1743089 ↗ |